Rivael v0.2.0: Blood-Brain Barrier Crossing Drug Candidates and Clinical Trial Gaps for DIPG/Diffuse Midline Glioma

Read full text Summarise with VIRAT
Authors: Hojun Yang
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Analysis of 1,097 biomedical papers identified 13 drug candidates that cross the blood-brain barrier and target pathways dysregulated in DIPG (Diffuse Intrinsic Pontine Glioma) but have never been tested in this disease. Three candidates — inavolisib (PI3K inhibitor), avutometinib (RAF/MEK inhibitor), and SCH772984 (ERK inhibitor) — have zero published papers connecting them to any form of pediatric glioma. Four additional candidates (cobimetinib, alpelisib, MDP5, mirdametinib) have fewer than 3 papers each. Six adult-to-pediatric translation gaps were identified where drugs studied in adult glioblastoma have never been tested in pediatric DIPG. DIPG has zero FDA-approved therapies and median survival of 9-11 months in children. All findings represent untested computational hypotheses requiring preclinical validation. The dataset includes plausibility assessments, PubMed novelty verification across 5 search variants per drug, suggested preclinical experiments, and pediatric-specific safety analyses.

Fields of Study & Subjects

Glioma Diagnosis and Treatment Computational Drug Discovery Methods Acute Lymphoblastic Leukemia research

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
22 March 2026
Language
EN
Document type
Dataset